Lewis H. Titterton, Jr. Buys 10,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, January 17th. The stock was bought at an average price of $2.57 per share, with a total value of $25,700.00. Following the completion of the acquisition, the director now owns 922,334 shares of the company’s stock, valued at $2,370,398.38. This trade represents a 1.10 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Anixa Biosciences Price Performance

Anixa Biosciences stock opened at $2.41 on Friday. The stock has a market cap of $77.55 million, a PE ratio of -6.18 and a beta of 0.90. The stock’s fifty day moving average is $2.80 and its two-hundred day moving average is $3.03. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last issued its earnings results on Friday, January 10th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.02. On average, research analysts expect that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a report on Tuesday, January 14th.

Institutional Trading of Anixa Biosciences

Several institutional investors have recently modified their holdings of ANIX. Concorde Asset Management LLC acquired a new stake in Anixa Biosciences during the 2nd quarter worth $31,000. International Assets Investment Management LLC grew its holdings in shares of Anixa Biosciences by 170.0% during the third quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after purchasing an additional 23,800 shares during the last quarter. Tyler Stone Wealth Management grew its holdings in shares of Anixa Biosciences by 100.0% during the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock worth $132,000 after purchasing an additional 21,008 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of Anixa Biosciences during the third quarter worth about $34,000. Finally, Westside Investment Management Inc. lifted its holdings in shares of Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares during the last quarter. Hedge funds and other institutional investors own 29.13% of the company’s stock.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.